XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value of Assets and Liabilities (Tables)
 6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Recurring and Nonrecurring Measured at Fair Value
The following table presents certain of our assets that are measured at fair value at June 30, 2022 and December 31, 2021, categorized by the level of inputs as defined in the fair value hierarchy under GAAP, used in the valuation of each asset.
As of June 30, 2022As of December 31, 2021
DescriptionCarrying AmountEstimated Fair ValueCarrying AmountEstimated Fair Value
Recurring Fair Value Measurements Assets:    
Investment in AlerisLife (Level 1) (1)
$12,830 $12,830 $31,540 $31,540 
Investment in unconsolidated joint venture (Level 3) (2)
$108,286 $108,286 $215,127 $215,127 
Investment in unconsolidated joint venture (Level 3) (3)
$50,473 $50,473 $— $— 
(1)Our 10,691,658 shares of common stock of AlerisLife Inc., or AlerisLife, are included in other assets, net in our condensed consolidated balance sheets, and are reported at fair value, which is based upon quoted market prices on The Nasdaq Stock Market LLC, or Nasdaq, (Level 1 inputs). During the three months ended June 30, 2022 and 2021, we recorded unrealized losses of $10,157 and $3,849, respectively, and during the six months ended June 30, 2022 and 2021, we recorded unrealized losses of $18,710 and $12,188, respectively, which are included in losses on equity securities, net in our condensed consolidated statements of comprehensive income (loss), to adjust the carrying value of our investment in AlerisLife common shares to their fair value. See Note 11 for further information about our investment in AlerisLife.
(2)The 10% equity interest we own in our Boston life science property joint venture is included in investments in unconsolidated joint ventures in our condensed consolidated balance sheet, and is reported at fair value, which is based on significant unobservable inputs (Level 3 inputs). The significant unobservable inputs used in the fair value analysis are a discount rate of 5.58%, an exit capitalization rate of 5.25%, a holding period of approximately 10 years and market rents. The assumptions made in the fair value analysis are based on the location, type and nature of the property, and current and anticipated market conditions, which are derived from appraisers, industry publications and our experience. See Note 2 for further information regarding this joint venture.
(3)The 20% equity interest we own in our 10 medical office and life science properties joint venture is included in investments in unconsolidated joint ventures in our condensed consolidated balance sheet, and is reported at fair value, which is based on significant unobservable inputs (Level 3 inputs). The significant unobservable inputs used in the fair value analysis are discount rates of between 5.67% and 8.93%, exit capitalization rates of between 4.75% and 6.00%, holding periods of approximately 10 years and market rents. The assumptions we made in the fair value analysis are based on the location, type and nature of each property, and current and anticipated market conditions, which are derived from appraisers, industry publications and our experience. See Note 2 for further information regarding this joint venture.
Schedule of Carrying Value and Fair Value of the Financial Instruments The fair values of these financial instruments approximated their carrying values in our condensed consolidated financial statements as of such dates, except as follows:
 As of June 30, 2022As of December 31, 2021
Description
Carrying Amount (1)
Estimated Fair Value
Carrying Amount (1)
Estimated Fair Value
Senior unsecured notes, 4.750% coupon rate, due 2024
$249,488 $224,353 $249,348 $257,695 
Senior unsecured notes, 9.750% coupon rate, due 2025
494,838 493,125 987,903 1,081,990 
Senior unsecured notes, 4.750% coupon rate, due 2028
492,836 368,125 492,199 491,480 
Senior unsecured notes, 4.375% coupon rate, due 2031
492,557 340,000 492,127 480,763 
Senior unsecured notes, 5.625% coupon rate, due 2042
342,374 227,850 342,183 309,260 
Senior unsecured notes, 6.250% coupon rate, due 2046
243,193 170,700 243,051 226,500 
Secured debts (2)
57,006 56,161 69,713 71,963 
 $2,372,292 $1,880,314 $2,876,524 $2,919,651 
(1)Includes unamortized net debt issuance costs, premiums and discounts.
(2)We assumed certain of these secured debts in connection with our acquisition of certain properties. We recorded the assumed mortgage notes at estimated fair value on the date of acquisition and we are amortizing the fair value adjustments, if any, to interest expense over the respective terms of the mortgage notes to adjust interest expense to the estimated market interest rates as of the date of acquisition.